NCT03993678View on ClinicalTrials.gov

Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors.

PHASE1/PHASE2Active, not recruitingINTERVENTIONAL
Enrollment

28

Participants

Timeline

Start Date

October 12, 2020

Primary Completion Date

December 30, 2025

Study Completion Date

December 31, 2025

Conditions
Advanced Solid Tumors
Interventions
DRUG

IP-001

Dose and route: Immediately (within 15 - 30 min) after thermal ablation, IP-001 will be injected in and around the ablated lesion. The amount of IP-001 injected depends on the dose level.

DEVICE

Thermal Ablation

"The medical device includes a laser unit. The system continuously measures the temperature of the tissue, guiding the user to perform precise and safe treatments.~Treatment time: 30 min"

Trial Locations (3)

7000

Kantonsspital Graubünden, Chur

CH-3010

Inselspital, Bern, Bern

CH-9007

Kantonsspital St. Gallen, Sankt Gallen

Sponsors

Collaborators (1)

Immunophotonics, Inc.
All Listed Sponsors
collaborator

Immunophotonics, Inc.

INDUSTRY

lead

Swiss Cancer Institute

OTHER

NCT03993678 - Intratumoral Injection of IP-001 Following Thermal Ablation in Patients With Advanced Solid Tumors. | Biotech Hunter | Biotech Hunter